HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing

HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing

Background: With the approval of the HIV-1 capsid inhibitor, lenacapavir, capsid sequencing will be required for managing lenacapavir-experienced individuals with detectable viremia. Successful sequence interpretation will require examining new capsid sequences in the context of previously published...

Full description

Bibliographic Details
Main Authors: Kaiming Tao, Soo-Yon Rhee, Philip L. Tzou, Zachary A. Osman, Sergei L. Kosakovsky Pond, Susan P. Holmes, Robert W. Shafer
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Viruses
Subjects:
HIV-1
capsid
lenacapavir
drug resistance
subtype
cytotoxic T lymphocytes
Online Access:https://www.mdpi.com/1999-4915/15/4/992

Internet

https://www.mdpi.com/1999-4915/15/4/992

Similar Items